Therapeutic Research

Abstract

GLP–1 analogue, liraglutide, improves glycemic control by stimulating endogenousinsulin secretion in a glucose–dependent manner, and inhibiting excessive caloric intake in type 2 diabetic（T2DM）patients. We retrospectively evaluated efficacy of liraglutide associated with body mass index（BMI）in Japanese T2DM patients treated with liraglutide over 12 weeks. The average of total daily dose of insulin was 11.8±5.4U/day before switching to liraglutide. The average regimen of insulin injection was 2.4±1.2 times/day. Liraglutide in the patients with no previous treatment or treated with oral hypoglycemic agents showed greater efficacy on glycemic control estimated by HbA1c（NGSP）than that in patients switching from insulin, but not on body weight reduction. BMI did not affect efficacy of liraglutide on body weight reduction and glycemic control in the patients with no previous treatment or treated with oral hypoglycemic agents. In contrast, body weight reduction by liraglutide was significantly higher in the obese patients（30kg/m2 ≦BMI）switching from insulin than the patients with normal BMI. We demonstrated efficacy of liraglutide on glycemic control and body weight reduction and the association with BMI in Japanese T2DM patients.